Compare BAK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAK | SGMT |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.3M | 648.1M |
| IPO Year | 2002 | 2021 |
| Metric | BAK | SGMT |
|---|---|---|
| Price | $1.82 | $8.95 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $1.90 | ★ $27.91 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $7.44 | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $4.50 |
| 52 Week High | $5.40 | $11.45 |
| Indicator | BAK | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 39.87 |
| Support Level | $1.40 | $8.69 |
| Resistance Level | $2.16 | $9.37 |
| Average True Range (ATR) | 0.11 | 0.67 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 82.47 | 16.05 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.